Sonazoid CEUS for Early HCC Surveillance

Starting soon · Not applicable

Conditions studied: Liver Cirrhosis, Liver Fibrosis

In brief

This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT/CEMRI every 12 months.

Key facts

Study ID

NCT07590284

Run by

Tianjin Third Central Hospital

People needed

556

Starts

2026-05-30

Expected to finish

2029-12-30

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cirrhotic patients diagnosed clinically or radiologically due to any etiology (patients with cirrhosis due to congenital fibrosis and patients with cirrhosis due to vascular causes were excluded).
• Age 18-80 years old.
• Able to receive regular imaging, including US, CEUS, and CECT or CEMRI or EOB-MRI, according to the diagnostic and treatment procedures.
• Obtained informed consent from the patient.

You may not qualify if…

• Patients with pathologic or enhanced imaging of established HCC who have not undergone curative treatment.
• Patients with known hypersensitivity to enhanced imaging contrast agents.
• Patients with severe cardiac, pulmonary or renal insufficiency that precludes CECT or CEMRI or EOB-MRI.
• Lactating and pregnant women.
• Those who are not suitable for enrollment as assessed by the investigator.
• Patients with egg or egg-product allergy, or with severe right-to-left cardiac shunt or intrapulmonary shunt.

Where it is running

• Tianjin Third Central Hospital — Tianjin, Tianjin Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.